Overview Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. Status: Completed Trial end date: 2017-04-01 Target enrollment: Participant gender: Summary To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR. Phase: Phase 2 Details Lead Sponsor: Sidney Kimmel Comprehensive Cancer CenterSidney Kimmel Comprehensive Cancer Center at Johns HopkinsTreatments: CarboplatinDocetaxelFluorouracilLeucovorin